Best of Precision Oncology Virtual Conference 2024

Friday, November 15, 2024

Event Type: Virtual
Conference Venue: Virtual Conference

Best of Precision Oncology Virtual Conference 2024

Event Landscape

Chaired by Dr. Heather McArthur, University of Texas Southwestern Medical Center, and Dr. Sumanta Pal, City of Hope Comprehensive Cancer Center, this international virtual conference will profile key foundational topics as well as emerging strategies associated with precision oncology. Attendees will be able to optimize diagnosis, treatment selection, and evidence-based management of patients with cancer using emerging diagnostic technologies to personalize and tailor therapies. The event will offer specific insights on precision oncology advances in key tumor areas including breast cancer, hematology, gastrointestinal cancer, genitourinary cancer, lung cancer, melanoma.

Icon Chair Speaker

Chairs

Type here

Learning Objectives

  1. State of the art tools for early detection of disease & monitoring of molecularly targeted therapies
  2. Precision oncology biomarkers to guide therapeutic decision making
  3. Precision therapies and understanding the pathways to guide new therapies

Scientific Agenda

Click below to learn more about the scheduled presentations and incredible speaker lineup at the Best of Precision Oncology Conference 2024.

Best of Precision Oncology Virtual Conference Co-Chairs

Dr. McArthur

Dr. Heather McArthur
Dr. McArthur, MD, MPH
Medical Oncologist, Clinical Director of Breast Cancer, Komen Distinguished Chair in Clinical Breast Research
University of Texas Southwestern Medical Center

Heather McArthur, MD, MPH is the Clinical Director of Breast Cancer and Komen Distinguished Chair in Clinical Breast Research at University of Texas Southwestern (UTSW) Medical Center. Dr. McArthur is a medical oncologist with a clinical practice dedicated to the care of patients with breast cancer. Her research activities are focused on innovations in the diagnosis and treatment of breast cancer, with a particular interest in novel immune therapy strategies. For example, she is currently evaluating the impact of tumor destruction with freezing (cryoablation) or radiation in combination with immune stimulation for the treatment of women with early stage breast cancer. It is hoped that by augmenting one’s immune response to the unique biologic features of one’s tumor, that an affected individual may develop long-term immunity against their tumor, and thus, be cured.

Dr. McArthur completed formal medical oncology training in Canada where she was awarded a highly competitive grant that funded an advanced fellowship at Memorial Sloan Kettering Cancer Center (MSKCC) in New York. Thereafter, she joined MSKCC as faculty where she developed the institutional breast cancer immunotherapy program before joining Cedars-Sinai Medical Center in Los Angeles in 2016 and UTSW in Dallas in 2021. She has a Master’s in Public Health with a focus on clinical trial design from Harvard University and has mentored many medical students, residents, fellows, and junior faculty in the conduct and reporting of several studies – two of which directly informed National Comprehensive Cancer Network treatment guidelines.

Dr. McArthur has held several leadership positions in the field including Co-Chair of a Breast International Group Immunotherapy Taskforce, member of a National Cancer Institute (NCI) Breast Cancer Immuno-Oncology (IO) Task Force, Society for Immunotherapy of Cancer (SITC) breast expert panel, and member of an Alliance for Clinical Trials in Oncology IO Committee. She has served the American Society of Clinical Oncology (ASCO) on the Annual Meeting IO Scientific Committee Leader, as co-chair of the Practice Health Committee, as member of the YIA/CDA Grant Selection Committee, as faculty at the Annual Meeting Grant Writing Workshop, as member of a Guideline Expert Panel, and member of Educational Book Reviewt Panels. She has participated in the ASCO Leadership Development Program; reviewed manuscripts for various high impact journals; authored numerous articles; and served on many study steering committees. She has designed, conducted, and reported on many studies in breast cancer and is currently the co-PI for a large, randomized, international phase 3 study exploring adjuvant chemotherapy with or without immune therapy for the treatment of triple negative breast cancer (IMpassion030).

Dr. Sumanta Pal

Dr. Sumanta Pal
MD, FASCO
Medical Oncologist
City of Hope Comprehensive Cancer Center

Sumanta Kumar Pal, M.D., is an internationally recognized leader in the area of genitourinary cancers, including kidney, and bladder cancer. He is co-director of City of Hope’s Kidney Cancer Program, Director of the Kidney and Bladder Cancer Disease Team and Vice Chair of Academic Affairs for the Department of Medical Oncology & Therapeutic Research.

Dr. Pal entered college at the age of 13 and began medical school at UCLA at the age of 17. After completing his residency training at UCLA, Dr. Pal completed a fellowship program in medical oncology at City of Hope’s comprehensive cancer center where he has remained on faculty since 2009.

Dr. Pal has published more than 500 PubMed cited articles that are featured in journals including: Cancer Discovery, The Journal of Clinical Oncology, The Lancet, Cancer Cell, and Nature Medicine.

Registration for Healthcare professionals can be completed above. Industry representatives (both sponsor and non-sponsor) must contact Bernadette Gregoris at [email protected]. Industry registrations will not be accepted through the website.

Sponsorship

​For sponsorship-related inquiries, please contact Bernadette Gregoris at [email protected].

Best of Precision Oncology Virtual Conference 2024 Sponsors

Gold sponsors

Amgen_logo_logotype

Silver sponsors

Astellas-Logo-3

Bronze sponsors

Merck_Logo_W-Anthem_Horizontal_TealGrey_RGB-1
All sales are final, refunds will not be accepted.

Please note mdBriefCase Group Inc. O/A Oncology Education cannot provide visa support for event attendees, including letters of invitation. Event attendees are solely responsible for obtaining any necessary documentation required for travel and participation in the event. No refunds shall be provided to individuals who are unable to attend.

Register Now